Meg Wood
Directeur/Membre du Conseil chez Aronora, Inc.
Profil
Meg Wood is a venture capital business development executive with experience creating emerging growth strategies for portfolio investment.
As the Managing Director of NYBC Ventures, Meg oversees deal execution and management.
Board Observer for NYBC Ventures portfolio companies Catena Biosciences and KaloCyte.
Previously, Meg built and managed a $50 million fund for scientific research and innovation for a rare disease as the Vice President of Business Development at CD Ventures.
She has deep experience deploying investment capital for mission-oriented fund structures.
Prior to her role at CD Ventures, she held positions at MPM Capital, Tufts Medical Center and Boston Medical Center.
She received Master’s degrees in social work and public health from Boston University and her BA from the College of Charleston.
Postes actifs de Meg Wood
| Sociétés | Poste | Début |
|---|---|---|
Nybc Ventures
 Nybc Ventures Investment ManagersFinance NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/04/2022 |
New York Blood Center, Inc.
 New York Blood Center, Inc. Medical/Nursing ServicesHealth Services New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY. | Private Equity Investor | 01/09/2021 |
Aronora, Inc.
 Aronora, Inc. Pharmaceuticals: MajorHealth Technology Aronora, Inc. operates as an early clinical stage translational biopharmaceutical company. It researches and develops proprietary biological therapeutics. The company was founded by Andras Gruber and Erik I. Tucker and is headquartered in Portland, OR. | Directeur/Membre du Conseil | 01/07/2023 |
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Consultant / Advisor | 01/08/2021 |
Thymmune Therapeutics
 Thymmune Therapeutics BiotechnologyHealth Technology Thymmune Therapeutics is a preclinical biotechnology company located in the US that is developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The American company's approach in ipsc-thymic cell manufacturing can generate off-the-shelf cells at scale. Thymmune is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune diseases. The company has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies. | Directeur/Membre du Conseil | 01/03/2023 |
KaloCyte, Inc.
 KaloCyte, Inc. BiotechnologyHealth Technology Kalocyte, Inc. operates as a pre-clinical stage healthcare biotech company. It provides artificial red blood cell substitutes used for trauma care related services. The company was founded in 2016 and is headquartered in Baltimore, MD. | Directeur/Membre du Conseil | 01/05/2022 |
Catena Biosciences, Inc.
 Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Directeur/Membre du Conseil | 01/04/2022 |
Anciens postes connus de Meg Wood
| Sociétés | Poste | Fin |
|---|---|---|
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Private Equity Investor | 01/08/2021 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/06/2016 |
Formation de Meg Wood
| Boston University | Graduate Degree |
| College of Charleston | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
New York Blood Center, Inc.
New York Blood Center, Inc. Medical/Nursing ServicesHealth Services New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY. | Health Services |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Finance |
KaloCyte, Inc.
KaloCyte, Inc. BiotechnologyHealth Technology Kalocyte, Inc. operates as a pre-clinical stage healthcare biotech company. It provides artificial red blood cell substitutes used for trauma care related services. The company was founded in 2016 and is headquartered in Baltimore, MD. | Health Technology |
Aronora, Inc.
Aronora, Inc. Pharmaceuticals: MajorHealth Technology Aronora, Inc. operates as an early clinical stage translational biopharmaceutical company. It researches and develops proprietary biological therapeutics. The company was founded by Andras Gruber and Erik I. Tucker and is headquartered in Portland, OR. | Health Technology |
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
Thymmune Therapeutics
Thymmune Therapeutics BiotechnologyHealth Technology Thymmune Therapeutics is a preclinical biotechnology company located in the US that is developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The American company's approach in ipsc-thymic cell manufacturing can generate off-the-shelf cells at scale. Thymmune is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune diseases. The company has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies. | Health Technology |
Nybc Ventures
Nybc Ventures Investment ManagersFinance NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts. | Finance |
